| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1267-1288, 2018 | 623 | 2018 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 334 | 2021 |
| Review of the diagnosis and treatment of periodic paralysis JM Statland, B Fontaine, MG Hanna, NE Johnson, JT Kissel, VA Sansone, ... Muscle & nerve 57 (4), 522-530, 2018 | 249 | 2018 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 202 | 2019 |
| Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial JM Statland, BN Bundy, Y Wang, DR Rayan, JR Trivedi, VA Sansone, ... Jama 308 (13), 1357-1365, 2012 | 197 | 2012 |
| Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons JJ Lawrence, F Saraga, JF Churchill, JM Statland, KE Travis, FK Skinner, ... Journal of Neuroscience 26 (47), 12325-12338, 2006 | 185 | 2006 |
| Primary lateral sclerosis MA Singer, JM Statland, GI Wolfe, RJ Barohn Muscle & Nerve: Official Journal of the American Association of …, 2007 | 180 | 2007 |
| Consensus-based care recommendations for adults with myotonic dystrophy type 1 T Ashizawa, C Gagnon, WJ Groh, L Gutmann, NE Johnson, G Meola, ... Neurology: Clinical Practice 8 (6), 507-520, 2018 | 177 | 2018 |
| Primary lateral sclerosis: consensus diagnostic criteria MR Turner, RJ Barohn, P Corcia, JK Fink, MB Harms, MC Kiernan, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (4), 373-377, 2020 | 175 | 2020 |
| Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS M Benatar, L Zhang, L Wang, V Granit, J Statland, R Barohn, A Swenson, ... Neurology 95 (1), e59-e69, 2020 | 173 | 2020 |
| Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis JM Statland, RJ Barohn, AL McVey, JS Katz, MM Dimachkie Neurologic clinics 33 (4), 735-748, 2015 | 136 | 2015 |
| A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis M Pasnoor, J He, L Herbelin, TM Burns, S Nations, V Bril, AK Wang, ... Neurology 87 (1), 57-64, 2016 | 131 | 2016 |
| Targeting protein homeostasis in sporadic inclusion body myositis M Ahmed, PM Machado, A Miller, C Spicer, L Herbelin, J He, J Noel, ... Science translational medicine 8 (331), 331ra41-331ra41, 2016 | 131 | 2016 |
| Cell type‐specific dependence of muscarinic signalling in mouse hippocampal stratum oriens interneurones JJ Lawrence, JM Statland, ZM Grinspan, CJ McBain The Journal of physiology 570 (3), 595-610, 2006 | 129 | 2006 |
| Facioscapulohumeral muscular dystrophy JM Statland, R Tawil CONTINUUM: Lifelong Learning in Neurology 22 (6), 1916-1931, 2016 | 116 | 2016 |
| Non-dystrophic myotonia: prospective study of objective and patient reported outcomes JR Trivedi, B Bundy, J Statland, M Salajegheh, DR Rayan, SL Venance, ... Brain 136 (7), 2189-2200, 2013 | 112 | 2013 |
| Facioscapulohumeral muscular dystrophy J Statland, R Tawil Neurologic clinics 32 (3), 721-728, 2014 | 106 | 2014 |
| A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression MD Weiss, EA Macklin, Z Simmons, AS Knox, DJ Greenblatt, N Atassi, ... Neurology 86 (16), 1474-1481, 2016 | 103 | 2016 |
| Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial J Diaz-Manera, PS Kishnani, H Kushlaf, S Ladha, T Mozaffar, V Straub, ... The Lancet Neurology 20 (12), 1012-1026, 2021 | 102 | 2021 |
| Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials BC Stunnenberg, J Raaphorst, HM Groenewoud, JM Statland, RC Griggs, ... Jama 320 (22), 2344-2353, 2018 | 101 | 2018 |
